การป้องกันลิ่มเลือดอุดตันในผู้ป่วยมะเร็งเม็ดโลหิตขาวชนิดมัยอีโลมาที่ได้รับยาปรับภูมิคุ้มกัน

การอ้างอิง/citation

ทักษิณ จันทร์สิงห์. (2563 ). การป้องกันลิ่มเลือดอุดตันในผู้ป่วยมะเร็งเม็ดโลหิตขาวชนิดมัยอีโลมาที่ได้รับยาปรับภูมิคุ้มกัน. วารสารไทยไภษัชยนิพนธ์ (Thai Bulletin of Pharmaceutical Sciences), 5(1), 49-65.

บทคัดย่อ

ABSTRACT

Multiple myeloma (MM) has been associated with an increase in the risk of venous thromboembolism (VTE) and death. Several risk factors of VTE include patients, diseases, and treatments such as patients receiving immunomodulatory drugs (IMiDs) in combination with high doses of dexamethasone or chemotherapy. The thromboprophylaxis protocols depend on risk stratifications. Patients with a standard risk of VTE are given 81-325 mg of aspirin daily. However, patients who are at higher risk are given a daily dose of low-molecular-weight heparins/LMWH (enoxaparin 40 mg), subcutaneously or dose-adjusted warfarin that has a target INR of 2.0-3.0. Medication is given for a minimum of 4-6 months or it can be given in combination with IMiDs during treatment for MM. Importantly, risk assessment for VTE and bleeding should be regularly monitored.

Keywords: thromboprophylaxis, venous thromboembolism, multiple myeloma, immunomodulatory drugs

Link to Publication 

PDF 

Thromboprophylaxis in Multiple Myeloma Patients Receiving Immunomodulatory Drugs

Faculty of Pharmacy, Siam University, Bangkok, Thailand

• The Perspective of Stakeholders towards the Problems and Solutions of Health Products Available Through Social Commerce in Thailand
• Prognostic Value of Serum Procalcitonin level for the Diagnosis of Bacterial Infections in Critically-ill Patients
• Formulation and in-vitro evaluation of fast dissolving tablets using superdisintegrant blend with effervescent materia
• Development of Nanoemulsions containing coconut oil with mixed mulsifiers: Effect of mixing speed on physical properties
• Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study
• Doripenem dosing regimens in Asian critically ill patients with continuous real replacement therapy
• Doripenem dosing in Asian critically ill patients with continuous renal replacement therapy
• Design and characterisation of electrospun shellac-polyvinylpyrrolidone blended micro/nanofibres loaded with monolaurin for application in wound healing
• General Knowledge for Pharmacists in Children Hematopoietic Stem Cell Transplantation